Bioiberica has announced that it has received Frost & Sullivan's 2025 European New Product Innovation Recognition in the innovative collagen solutions industry for its outstanding achievements in clinical validation, ingredient differentiation and evidence-based product development.
The company said in a release that the achievement reflects its consistent leadership in advancing scientifically validated collagen ingredients, strengthening its competitive position and enabling customer-centric innovation in a complex and rapidly evolving European joint health and nutrition landscape.
Each year, Frost & Sullivan honours a company with the New Product Innovation Recognition for outstanding strategy and execution, achieving differentiation, customer value and competitive advantage.
This award celebrates organisations that drive their industries forward through credible innovation and growth.
Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and execution.
This award from Frost & Sullivan recognises Bioiberica for its exceptional work in collagen innovation, manufacturing transparency and customer collaboration.
Bioiberica excelled at integrating a long-term scientific strategy with market needs while executing with precision, consistency and regulatory discipline.
"Bioiberica distinguishes Collavant n2 by providing mechanistic clarity and efficacy both in terms of joint comfort and potential cartilage preservation, setting it apart in a market that often lacks transparent clinical substantiation," said Sreedevi Kakkad, Senior Research Analyst, TechVision at Frost & Sullivan.
Frost & Sullivan said that Bioiberica showed strong adaptability in the European collagen solutions market, driven by a long-term growth strategy focused on science-based innovation, clinical research and vertically integrated manufacturing.
The company's ongoing investment in native type II collagen research and the production of pharmaceutical-grade products has enabled it to serve both clinical and lifestyle nutrition segments, while ensuring full traceability and compliance with regulatory standards.
Collavant n2 is a native type II collagen ingredient derived from chicken sternum cartilage, preserves the collagen's molecular structure and delivers efficacy at a low daily dose of 40 milligrams through an immune-mediated mechanism of action.
Unlike denatured collagen peptides that rely on gram-level dosing, Collavant n2 offers a differentiated formulation strategy supported by randomised, controlled clinical trials demonstrating support in joint comfort, mobility and functional performance.
"We're honoured to receive this prestigious award and we'd like to thank everyone who has contributed to this milestone—from our exceptional scientists and technical experts to our production specialists, regional distributors and more," commented Antonio Vendrell, Marketing & Communications Director at Bioiberica.
To us, collagen is much more than just a molecule. It is a tool that, through in-depth research and refinement, unlocks virtually limitless opportunities for health and wellbeing innovation.
"Through our continuous efforts to clinically characterise the benefits of Collavant n2, as well as our initiatives to dispel common myths and misconceptions in the collagen market, we hope to empower our industry partners to unlock the next generation of collagen innovation."
Bioiberica emphasises its dedication to customer success, which strengthens its market position. The company assists manufacturers of finished products by providing clinical validation, formulation guidance, regulatory documentation and various validated delivery formats, such as capsules, gummies, functional foods and lifestyle-oriented nutrition products.
This collaborative approach minimises formulation risks and enables partners to speed up commercialisation while ensuring scientific credibility and compliance with European regulations.
BioIberica has a vertically integrated supply chain within the SARIA Group, enabling full control over sourcing, processing and production of Collavant n2 in Europe. They utilise the Independent NutraStrong Collagen Verification to enhance ingredient consistency, traceability and customer trust.
Frost & Sullivan's report stated that "Bioiberica demonstrates a comprehensive approach to innovation in the European collagen solutions market, integrating scientific rigour, operational excellence, customer engagement and adaptive product development. Clinically validated native type II collagen differentiates Collavant n2, with research confirming efficacy at low doses and targeted biological mechanisms."
The evaluation also praised Bioiberica's vertically integrated manufacturing, stringent quality controls and sustainability-driven practices.